摘要
目的探讨尤瑞克林联合依达拉奉治疗对急性进展性脑梗死患者的临床价值分析。方法116例急性进展性脑梗死患者,按照不同治疗用药方案分为对照组和观察组各58例。所有患者均给予常规抗血小板凝集阿司匹林300 mg口服治疗,对照组加用依达拉奉治疗,观察组在对照组基础上联合尤瑞克林治疗,疗程均为14天。比较两组临床疗效、炎性因子、血管内皮细胞功能、美国神经功能缺损评分量表(NIHSS)评分、日常生活活动能力量表(ADL)评分。结果对照组临床总有效率低于观察组(P<0.05)。治疗后两组白细胞介素(IL) 6、IL 10、肿瘤坏死因子 α(TNF α)水平及NIHSS评分较治疗前均降低,且观察组低于对照组;血管内皮细胞生长因子(VEGF)、一氧化氮(NO)水平及ADL评分较治疗前均升高,且观察组高于对照组(P<0.05)。两组治疗过程中均未出现不良反应。结论急性进展性脑梗死患者采取尤瑞克林联合依达拉奉进行治疗疗效显著,有效改善和提高炎性因子、血管内皮功能,且无严重不良反应。
Objective To investigate the clinical value of urinary kallindinogenase combined with edaravone in the treatment of patients with acute progressive cerebral infarction.Methods One hundred and sixteen patients with acute progressive cerebral infarction were divided into control or observation group,58 in each group according to the different medications.All patients were given treatment with 300 mg aspirin orally and conventional antiplatelet agglutination.The control group was supplemented with edaravone while the observation group was supplemented with urinary kallindinogenase on the basis of the treatment of the control group.Both groups were treated for 14 days.The clinical efficacy,inflammatory factors,function of vascular endothelial cell,National Institute of Health stroke scale(NIHSS)and Activity of Daily Living(ADL)scores were compared before and after treatment between the two groups.Re sults The total effective rate of the control group was significantly lower than that of the observation group(P<0.05).After treatment,the levels of IL 10,IL 6 and TNF ain the two groups were significantly decreased when compared to those before treatment,and the levels in observation group were significantly lower than those in the control group(P>0.05).The vascular endothelial growth factor(VEGF)and nitric oxide(NO),and ADL were significantly higher than those before treatment,and the levels in the observation group were signifi cantly higher than those in the control group(P<0.05).The adverse reactions did not occur during the treatment in both groups.Conclusion Urinary kallindinogenase combined with edaravone in the treatment of patients with acute progressive cerebral infarction has significant effect.It effectively improves inflammatory factors and vascular endothelial function without serious adverse reactions.
作者
王洪军
李成刚
龚自力
WANG Hong jun;LI Cheng gang;GONG Zi li(Department of Neurology,Fengdu County People's Hospital,Chongqing 408200,China;Department of Neurology,The Second Affiliated Hospital,Army Medical University,Chongqing 400037,China)
出处
《实用医院临床杂志》
2019年第6期154-157,共4页
Practical Journal of Clinical Medicine
关键词
尤瑞克林
依达拉奉
急性进展性脑梗死
Urinary kallindinogenase
Edaravone
Acute progressive cerebral infarction
